469
Views
6
CrossRef citations to date
0
Altmetric
Original Article: Clinical

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

, , , , , , , & show all
Pages 390-394 | Received 25 Sep 2013, Accepted 08 Apr 2014, Published online: 17 Jul 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yanling Ren, Huifang Jiang, Fangjing Shi, Li Ye, Yingwan Luo, Xinping Zhou, Chen Mei, Liya Ma, Weilai Xu, Peipei Lin, Chao Hu, Jie Jin & Hongyan Tong. (2019) Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting. Leukemia & Lymphoma 60:7, pages 1731-1739.
Read now

Articles from other publishers (5)

Hui Liu, Hao Jiang, Hongyan Tong, Ruixiang Xia, Linhua Yang, Hongguo Zhao, Jian Ouyang, Hai Bai, Hui Sun, Li Hou, Ming Jiang, Yun Zeng, Zhuogang Liu, Aibin Liang, Yinghua Xie, Kang Yu, Zhimin Zhai, Li Liu, Jinsong Jia, Rong Fu & Zonghong Shao. (2023) Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial. Cancer Medicine 12:13, pages 13885-13893.
Crossref
Kaiji Zhang, Ying Lian, Xiaohong Guan, Qian Hu, Lihua Lei, Li Tao, Dong He, Juan Lin, Zheng Hou, Lirong Ren, Xiaoxiao Liu, Qian Ren, Lin Pan, Xiaoli Fei, Mei Xiong, Shunzhu Wen & Jinzhu Cao. (2020) Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases. Annals of Hematology 99:11, pages 2539-2546.
Crossref
Kamel Laribi, Delphine Bolle, Mustafa Alani, Habib Ghnaya, Anne Besançon, Jonathan Farhi, Kayane Mheidly, Nathalie Denizon & Alix Baugier de Materre. (2019) Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine. Cancer Medicine 8:5, pages 2188-2195.
Crossref
Myrna Candelaria, Sebastian Burgos, Mayra Ponce, Ramiro Espinoza & Alfonso Dueñas-Gonzalez. (2017) Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). Annals of Hematology 96:11, pages 1825-1832.
Crossref
Bryan Oronsky, Carolyn M. Ray, Alexander I. Spira, Jane B. Trepel, Corey A. Carter & Hope M. Cottrill. (2017) A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer. Medical Oncology 34:6.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.